GRIFOLS S A/S (NASDAQ:GRFS) Shares Sold by Lenox Wealth Management Inc.

Lenox Wealth Management Inc. trimmed its holdings in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 2.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 230,186 shares of the biotechnology company’s stock after selling 6,487 shares during the period. GRIFOLS S A/S makes up about 1.3% of Lenox Wealth Management Inc.’s portfolio, making the stock its 17th biggest position. Lenox Wealth Management Inc.’s holdings in GRIFOLS S A/S were worth $4,612,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AKO Capital LLP lifted its stake in shares of GRIFOLS S A/S by 5.5% in the 2nd quarter. AKO Capital LLP now owns 12,562,923 shares of the biotechnology company’s stock valued at $265,078,000 after purchasing an additional 654,497 shares during the period. Farallon Capital Management LLC lifted its stake in shares of GRIFOLS S A/S by 5.3% in the 2nd quarter. Farallon Capital Management LLC now owns 3,080,083 shares of the biotechnology company’s stock valued at $64,990,000 after purchasing an additional 153,731 shares during the period. Morgan Stanley lifted its stake in shares of GRIFOLS S A/S by 65.2% in the 2nd quarter. Morgan Stanley now owns 1,827,582 shares of the biotechnology company’s stock valued at $38,562,000 after purchasing an additional 721,604 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of GRIFOLS S A/S by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,615,633 shares of the biotechnology company’s stock valued at $33,233,000 after purchasing an additional 57,155 shares during the period. Finally, Man Group plc lifted its stake in shares of GRIFOLS S A/S by 1.4% in the 2nd quarter. Man Group plc now owns 1,472,468 shares of the biotechnology company’s stock valued at $31,069,000 after purchasing an additional 19,997 shares during the period. Institutional investors and hedge funds own 18.00% of the company’s stock.

NASDAQ:GRFS traded up $0.12 during trading hours on Friday, reaching $21.52. 834,900 shares of the company were exchanged, compared to its average volume of 1,166,989. The stock’s 50-day moving average is $20.70 and its 200-day moving average is $20.44. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $23.03. The company has a current ratio of 2.62, a quick ratio of 0.96 and a debt-to-equity ratio of 1.30. The firm has a market cap of $14.78 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 1.37 and a beta of 1.08.

Several equities analysts recently issued reports on the stock. Berenberg Bank upgraded shares of GRIFOLS S A/S to a “buy” rating in a research note on Wednesday, October 30th. Zacks Investment Research cut shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. BidaskClub upgraded shares of GRIFOLS S A/S from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 16th. ValuEngine upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Santander upgraded shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Monday, October 28th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. GRIFOLS S A/S presently has an average rating of “Hold” and a consensus price target of $20.75.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Recommended Story: Range Trading

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply